IP Group

Cadence Demonstrates IP Test Silicon for PCI Express 6.0 Specification on TSMC N5 Process

Thursday, October 21, 2021 - 3:45pm

Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced the immediate availability of Cadence IP supporting the PCI Express (PCIe)6.0 specification on the TSMC N5 process.

Key Points: 
  • Cadence Design Systems, Inc. (Nasdaq: CDNS) today announced the immediate availability of Cadence IP supporting the PCI Express (PCIe)6.0 specification on the TSMC N5 process.
  • The 5nm PCIe 6.0 PHY test chip silicon from Cadence demonstrated excellent electrical performance across all PCIe rates.
  • The Cadence IP for the PCIe 6.0 specification supports the companys Intelligent System Design strategy, which enables SoC design excellence.
  • Cadence, the Cadence logo and the other Cadence marks found at www.cadence.com/go/trademarks are trademarks or registered trademarks of Cadence Design Systems, Inc. PCI Express and PCIe are registered trademarks of PCI-SIG.

Crescendo Biologics Announces That Zai Lab Has Achieved Proof-of-Concept for ZL-1102 (Humabody®, CB001) in a Phase 1b Clinical Trial in Psoriasis Patients

Thursday, October 21, 2021 - 8:00am

The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP).

Key Points: 
  • The Phase 1b trial was a first-in-human study to evaluate the safety, pharmacokinetics and efficacy of a topical formulation of ZL-1102 in adults with mild-to-moderate chronic plaque psoriasis (CPP).
  • Further information can be found in the press release issued by Zai Lab on 20 October 2021.
  • Theodora Harold, Chief Executive Officer at Crescendo, said: This is a very exciting day for Crescendo.
  • Under the terms of that agreement, Crescendo granted to Zai Lab a worldwide exclusive license to develop and commercialize ZL-1102 for all indications.

Crescendo Biologics Announces Prestigious New Collaboration With the Institute of Cancer Research, London

Wednesday, October 20, 2021 - 8:00am

Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces a new translational science collaboration with The Institute of Cancer Research, London, one of the worlds most influential cancer research organisations.

Key Points: 
  • Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces a new translational science collaboration with The Institute of Cancer Research, London, one of the worlds most influential cancer research organisations.
  • Working together, Crescendo and The Institute of Cancer Research (ICR) will further characterise the non-clinical pharmacology of CB307, Crescendos first-in-class lead programme.
  • Next generation immunotherapies could offer much-needed new treatment options to patients with castration-resistant prostate cancer, as well as other cancer types with high prevalence.
  • Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody therapeutics.

Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis

Tuesday, October 19, 2021 - 12:00pm

Oxford, UK 19 October 2021: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option to license Oxford Biomedicas lentiviral vector technology to manufacture, register and commercialise BI 3720931, a lentiviral vector-based gene therapy for the treatment of cystic fibrosis (CF).

Key Points: 
  • Oxford, UK 19 October 2021: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option to license Oxford Biomedicas lentiviral vector technology to manufacture, register and commercialise BI 3720931, a lentiviral vector-based gene therapy for the treatment of cystic fibrosis (CF).
  • Under the terms of the option and license agreement with Boehringer Ingelheim, originally announced in August 2018 , Boehringer Ingelheim will pay Oxford Biomedica an option exercise fee of 3.5 million.
  • In parallel, Boehringer Ingelheim has also exercised its option to license intellectual property and know-how from IP Group and the UK Cystic Fibrosis Gene Therapy Consortium relating to the same lentiviral vector-based product candidate for the treatment of CF.
  • Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim, said: Since 2018, Boehringer Ingelheim has sponsored research and development activities with the UK Cystic Fibrosis Gene Therapy Consortium and Oxford Biomedica.

Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis

Tuesday, October 19, 2021 - 7:00am

The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development.

Key Points: 
  • The GTC is additionally contributing its knowledge in pre-clinical research and clinical gene therapy development.
  • OXB is adding its leading competence in manufacturing lentiviral vector-based therapies to Boehringer Ingelheims expertise in the development of novel breakthrough therapies for respiratory diseases.
  • This partnership is central to our companys mission of delivering life changing gene therapies to patients and has the potential to provide a new therapeutic option for many cystic fibrosis patients globally.
  • David Ramsden, Chief Executive of the Cystic Fibrosis Trust said: It is great news that Boehringer Ingelheim have committed to the next stage of the development of a gene therapy treatment for people with cystic fibrosis.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:30pm

ALAMEDA, Calif. and CAMBRIDGE, England, Oct. 14, 2021 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer. The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target. 

Key Points: 
  • The collaboration will focus initially on ADAR1, advancing early work by STORM applying its proprietary RNA epigenetic platform, as well as explore an additional undisclosed target.
  • "STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline," said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

Thursday, October 14, 2021 - 1:00pm

Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.

Key Points: 
  • Exelixis, Inc. (Nasdaq: EXEL) and STORM Therapeutics (STORM) today announced that they have entered into an exclusive collaboration and license agreement under which the parties will discover and advance novel drug leads intended for the treatment of cancer.
  • STORM has established industry-leading expertise and know-how through ground-breaking research on the discovery of small molecule therapies targeting RNA-modifying enzymes.
  • This collaboration with Exelixis validates the significant value of our technology platform and expanding pipeline, said Keith Blundy, Director and Chief Executive Officer, STORM Therapeutics.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered U.S. trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

Hakluyt opens new office in Washington, D.C.

Thursday, October 14, 2021 - 9:00am

Andrew joined Hakluyt in 2017, and has worked for the firm in New York and Dallas.

Key Points: 
  • Andrew joined Hakluyt in 2017, and has worked for the firm in New York and Dallas.
  • Prior to Hakluyt, he served as US Deputy Assistant Secretary of Defense for the Middle East.
  • He has also worked for Boston Consulting Group in its Washington office, and as an officer in the US Army.
  • Varun Chandra, Hakluyt's managing partner, said: "North America has been an increasingly important market for Hakluyt for many years, and I'm delighted that Hakluyt now has an office in the US capital.

Hakluyt opens new office in Washington, D.C.

Thursday, October 14, 2021 - 9:00am

Andrew joined Hakluyt in 2017, and has worked for the firm in New York and Dallas.

Key Points: 
  • Andrew joined Hakluyt in 2017, and has worked for the firm in New York and Dallas.
  • Prior to Hakluyt, he served as US Deputy Assistant Secretary of Defense for the Middle East.
  • He has also worked for Boston Consulting Group in its Washington office, and as an officer in the US Army.
  • Varun Chandra, Hakluyt's managing partner, said: "North America has been an increasingly important market for Hakluyt for many years, and I'm delighted that Hakluyt now has an office in the US capital.